What is claimed is:

1. A method of making an antibody, said method comprising culturing a host cell comprising polynucleotide comprising (1) a first translation initiation region (TIR) operably linked to a polynucleotide encoding an antibody heavy chain, wherein the TIR comprises a DsbA variant co-translation prokaryotic secretion signal sequence; and (2) a second TIR operably linked to a polynucleotide encoding an antibody light chain, wherein the second TIR comprises a co-translation or post-translation prokaryotic secretion signal sequence, whereby upon expression of the antibody in a host cell, the heavy and light chains are folded and assembled to form a biologically active antibody.

2. The method of claim 1, wherein the first translation initiation region comprises sequence of one of SEQ ID NOs: 36-39, 41 and 42.

3. The method of any one of claims 1and 2, wherein the second translation initiation region comprises a STII, DsbA, MalE or PhoA variant signal sequence.

4. The method of claim 3, wherein the second translation initiation region comprises sequence of one of SEQ ID NOs. 1-14, 16-24, 26-39, and 41-42.

5. The method of any one of claims 1-4, wherein the host cell further comprises (3) a third translation initiation region operably linked to a polynucleotide encoding a Fc polypeptide.

6. The method of claim 5, wherein the third translation initiation region comprises a STII, ~~PhoI~~ PhoA or DsbA variant signal sequence.

7. The method of claim 6, wherein the third translation initiation region comprises sequence of one of SEQ ID NOs: 23, 24, 26-39, 41 and 42.

8. The method of any one of claims 1-7, wherein the first and second translation initiation regions provide equal translation strengths.

9. The method of any one of claims 6-8, wherein the first, second and third translation initiation regions provide equal translation strengths.

10. The method of any one of claims 1-9, wherein the polynucleotide in the host cell further comprises a promoter.

11. The method of claim 10, wherein the promoter is a prokaryotic promoter selected from the group consisting of phoA, tac, lpp, lac-lpp, lac, ara, and T7 promoter.

25. The polynucleotide of any one of claims 23 and 24, wherein the second translation initiation region comprises a STII, DsbA, MalE or PhoA variant signal sequence.

26. The polynucleotide of claim 25, wherein the second translation initiation region comprises sequence of one of SEQ ID NOs. 1-14, 16-24, 26-39, and 41-42.

27. The polynucleotide of any one of claims 23-26, wherein the host cell further comprises (3) a third translation initiation region operably linked to a polynucleotide encoding a Fc polypeptide.

28. The method of claim 27, wherein the third translation initiation region comprises a STII, ~~PhoI~~ PhoA or DsbA variant signal sequence.

29. The polynucleotide of claim 27, wherein the third translation initiation region comprises sequence of one of SEQ ID NOs: 23, 24, 26-39, 41 and 42.

30. The polynucleotide of any one of claims 23-29, wherein the first and second translation initiation regions provide equal translation strengths.

31. The polynucleotide of any one of claims 27-29, wherein the first, second and third translation initiation regions provide equal translation strengths.

32. The polynucleotide of any one of claims 23-31, wherein the polynucleotide further comprises a promoter.

33. The polynucleotide of claim 32, wherein the promoter is a prokaryotic promoter selected from the group consisting of phoA, tac, lpp, lac-lpp, lac, ara, and T7 promoter.

34. The polynucleotide of any one of claims 23-33, wherein the host cell further comprises a polynucleotide encoding at least one prokaryotic polypeptide selected from the group consisting of DsbA, DsbC, DsbG and FkpA.

35. The polynucleotide of claim 34, wherein the polynucleotide encodes both DsbA and DsbC.

36. The polynucleotide of any one of claims 1-35, wherein the antibody is a monoclonal antibody.

37. The polynucleotide of claim 36, wherein the antibody is a chimeric antibody, an affinity matured antibody, a bispecific antibody, humanized antibody, and antibody fragment or a human antibody.

38. The polynucleotide of claim 37, wherein the antibody is a one-armed antibody.

39. The polynucleotide of claim 37, wherein the antibody is a bispecific antibody.

~~40. An antibody obtained by a method of any one of claims 1-22.~~

~~41. A pharmaceutical composition comprising the antibody of claim 40.~~

~~42. A pharmaceutical composition of claim 41, which comprises a carrier, excipient or stabilizer.~~

4043. A host cell comprising the polynucleotide of any one of claims 23-39.

5